US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
JP2703764B2
(ja)
|
1986-04-28 |
1998-01-26 |
シータス オンコロジー コーポレイション |
補体成分C5aに対するモノクローナル抗体
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
DE69029036T2
(de)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
Bispezifische reagenzien für die aids-therapie
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
EP0586505A1
(en)
|
1991-05-14 |
1994-03-16 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
WO1993000109A1
(en)
|
1991-06-28 |
1993-01-07 |
Genentech, Inc. |
Method of stimulating immune response using growth hormone
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
ATE244763T1
(de)
|
1992-02-11 |
2003-07-15 |
Cell Genesys Inc |
Erzielen von homozygotem durch zielgerichtete genetische ereignisse
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
US5981176A
(en)
|
1992-06-17 |
1999-11-09 |
City Of Hope |
Method of detecting and discriminating between nucleic acid sequences
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
MX9305070A
(es)
|
1992-08-21 |
1994-04-29 |
Genentech Inc |
Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
|
CA2149329C
(en)
|
1992-11-13 |
2008-07-15 |
Darrell R. Anderson |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
AU6048294A
(en)
|
1992-11-25 |
1994-06-22 |
Amgen Boulder Inc. |
Modified insulin-like growth factors
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
JPH08508296A
(ja)
|
1993-04-07 |
1996-09-03 |
アムジエン・ブルダー・インコーポレーテッド |
インシュリン様成長因子結合タンパク質の使用方法
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
US6045996A
(en)
|
1993-10-26 |
2000-04-04 |
Affymetrix, Inc. |
Hybridization assays on oligonucleotide arrays
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
WO1995025540A1
(en)
|
1994-03-23 |
1995-09-28 |
Alexion Pharmaceuticals, Inc. |
Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
US5919623A
(en)
*
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
US5849483A
(en)
|
1994-07-28 |
1998-12-15 |
Ig Laboratories, Inc. |
High throughput screening method for sequences or genetic alterations in nucleic acids
|
US5589330A
(en)
|
1994-07-28 |
1996-12-31 |
Genzyme Corporation |
High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides
|
US5897475A
(en)
|
1994-10-05 |
1999-04-27 |
Antex Biologics, Inc. |
Vaccines comprising enhanced antigenic helicobacter spp.
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
US6239273B1
(en)
|
1995-02-27 |
2001-05-29 |
Affymetrix, Inc. |
Printing molecular library arrays
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
ATE455171T1
(de)
|
1995-09-21 |
2010-01-15 |
Genentech Inc |
Varianten des menschlichen wachstumshormons
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US6152681A
(en)
|
1996-05-03 |
2000-11-28 |
Arrowhead Systems, Llc |
Container sweep for a palletizer and method
|
WO2002008284A2
(en)
|
2000-07-20 |
2002-01-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
WO2001036432A2
(en)
|
1999-11-19 |
2001-05-25 |
Human Genome Sciences, Inc. |
18 human secreted proteins
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
ES2230631T3
(es)
|
1997-03-20 |
2005-05-01 |
F. Hoffmann-La Roche Ag |
Cebadores modificados.
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
EP0973804B1
(en)
|
1997-04-07 |
2006-12-27 |
Genentech, Inc. |
Anti-vegf antibodies
|
DE69830315T2
(de)
|
1997-06-24 |
2006-02-02 |
Genentech Inc., San Francisco |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
NZ502375A
(en)
|
1997-07-14 |
2001-11-30 |
Bolder Biotechnology Inc |
The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
|
DE69823206T2
(de)
|
1997-07-25 |
2004-08-19 |
Affymetrix, Inc. (a Delaware Corp.), Santa Clara |
Verfahren zur herstellung einer bio-informatik-datenbank
|
ATE280246T1
(de)
|
1997-08-15 |
2004-11-15 |
Affymetrix Inc |
Polymorphismuserkennung mit hilfe cluster-analyse
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
JP2001513576A
(ja)
|
1997-08-26 |
2001-09-04 |
グリアテック インコーポレイテッド |
側副経路を介する補体活性化を阻害するためのプロセス
|
ATE419009T1
(de)
|
1997-10-31 |
2009-01-15 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
ES2305608T3
(es)
|
1997-11-21 |
2008-11-01 |
Genentech, Inc. |
Antigenos tipo a-33 y sus utilizaciones farmacologicas.
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
JP2002502589A
(ja)
|
1998-02-09 |
2002-01-29 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
45個のヒト分泌タンパク質
|
EP3056516A1
(en)
|
1998-02-20 |
2016-08-17 |
Genentech, Inc. |
Inhibitors of complement activation
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
PT1490386E
(pt)
|
1998-03-10 |
2008-11-24 |
Genentech Inc |
Novos polipéptidos e ácidos nucleicos que os codificam
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
WO2000012703A2
(en)
|
1998-08-27 |
2000-03-09 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
MXPA01006006A
(es)
|
1998-12-14 |
2004-08-12 |
Genetics Inst |
Cadena receptora de citocina.
|
AU777006B2
(en)
|
1998-12-16 |
2004-09-30 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
ES2281704T3
(es)
|
1998-12-22 |
2007-10-01 |
Genentech, Inc. |
Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasicas.
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6136541A
(en)
|
1999-02-22 |
2000-10-24 |
Vialogy Corporation |
Method and apparatus for analyzing hybridized biochip patterns using resonance interactions employing quantum expressor functions
|
CA2362427A1
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU782139B2
(en)
|
1999-03-11 |
2005-07-07 |
Merck Serono Sa |
Vascular adhesion molecules and modulation of their function
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
AU2883900A
(en)
|
1999-07-07 |
2001-01-30 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
WO2001025485A2
(en)
|
1999-10-06 |
2001-04-12 |
Amersham Biosciences Corp |
Method for detecting mutations using arrayed primer extension
|
US6709816B1
(en)
|
1999-10-18 |
2004-03-23 |
Affymetrix, Inc. |
Identification of alleles
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PRODUCING A POLYPEPTIDE
|
EP2228446A1
(en)
|
1999-12-01 |
2010-09-15 |
Genentech, Inc. |
Secreted and transmembrane polypeptieds and nucleic acids encoding the same
|
US20050036991A1
(en)
|
2000-02-10 |
2005-02-17 |
Fodor William L |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
US6998468B2
(en)
|
2000-03-23 |
2006-02-14 |
Tanox, Inc. |
Anti-C2/C2a inhibitors of complement activation
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
ES2316446T3
(es)
|
2000-04-29 |
2009-04-16 |
University Of Iowa Research Foundation |
Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
|
EP1309620A2
(en)
|
2000-06-23 |
2003-05-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP2281840A3
(en)
|
2000-10-10 |
2012-05-23 |
Genentech, Inc. |
Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
JP2004532608A
(ja)
|
2000-10-13 |
2004-10-28 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ヒト化抗LT−β−R抗体
|
KR20030074693A
(ko)
|
2000-12-28 |
2003-09-19 |
알투스 바이올로직스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
CN100391537C
(zh)
|
2001-08-17 |
2008-06-04 |
建南德克公司 |
结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
|
EP2348043A1
(en)
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
APO-2 ligand variants and uses thereof
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
WO2004022594A2
(en)
|
2002-09-06 |
2004-03-18 |
Cytos Biotechnology Ag |
Immune modulatory compounds and methods
|
WO2004041160A2
(en)
|
2002-10-30 |
2004-05-21 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
US6864748B2
(en)
|
2003-01-31 |
2005-03-08 |
Lsi Logic Corporation |
Differential current amplifier with common mode rejection and high frequency boost
|
AU2004216176B2
(en)
|
2003-02-21 |
2008-04-03 |
Genentech, Inc. |
Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
|
RU2232991C1
(ru)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Способ определения функциональной активности фактора d комплемента человека
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
EP2267028A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Dual specific single domain antibodies (dAb) conjugated to PEG
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
EP1791565B1
(en)
|
2004-09-23 |
2016-04-20 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
BRPI0518289A2
(pt)
|
2004-11-18 |
2008-11-11 |
Univ Yale |
mÉtodos e composiÇÕes para o tratamento de desordens oculares
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
EP2319940A1
(en)
|
2005-01-04 |
2011-05-11 |
Hitachi Chemical Company, Ltd. |
Primer generation rolling circle amplification
|
CN103920142A
(zh)
|
2005-02-14 |
2014-07-16 |
爱荷华大学研究基金会 |
治疗和诊断年龄相关性黄斑变性的方法和试剂
|
CN101495651A
(zh)
|
2005-06-08 |
2009-07-29 |
匹兹堡大学 |
染色体10q26上的年龄-相关黄斑病变(ARM)易感基因
|
CN105582523B
(zh)
|
2005-10-08 |
2022-04-15 |
阿佩利斯制药公司 |
用于眼部病症的补体抑制素和其类似物
|
PL2500030T5
(pl)
|
2005-11-04 |
2019-02-28 |
Genentech, Inc. |
Zastosowanie inhibitorów drogi aktywacji dopełniacza w leczeniu chorób oczu
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
EP2004643A1
(en)
|
2006-03-31 |
2008-12-24 |
Novartis AG |
Organic compounds
|
LT2944306T
(lt)
|
2006-06-16 |
2021-02-25 |
Regeneron Pharmaceuticals, Inc. |
Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
|
KR20090060453A
(ko)
|
2006-09-25 |
2009-06-12 |
메디뮨 엘엘씨 |
안정화된 항체 제제 및 그것의 용도
|
CN106084055A
(zh)
|
2006-11-02 |
2016-11-09 |
健泰科生物技术公司 |
人源化的抗‑d因子抗体
|
KR20100014486A
(ko)
*
|
2007-04-30 |
2010-02-10 |
알콘 리서치, 리미티드 |
보체 인자 d의 저해제를 사용한 연령 관련 황반변성의 치료
|
CA2705500A1
(en)
|
2007-05-11 |
2008-11-20 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
AR066660A1
(es)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
CN104231082B
(zh)
|
2007-05-24 |
2018-12-21 |
埃博灵克斯股份有限公司 |
用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
|
US20110092446A1
(en)
*
|
2007-07-20 |
2011-04-21 |
Cedric Francois |
Compositions and methods for treatment of trauma
|
US20090203001A1
(en)
*
|
2007-08-24 |
2009-08-13 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
AU2009251499B2
(en)
*
|
2008-04-18 |
2015-07-16 |
The General Hospital Corporation |
Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
|
US20110294682A1
(en)
|
2008-04-28 |
2011-12-01 |
The General Hospital Corporation |
Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
RU2514658C2
(ru)
|
2008-06-25 |
2014-04-27 |
ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи |
Оптимизация растворимости иммуносвязывающих средств
|
CN102186996A
(zh)
|
2008-10-20 |
2011-09-14 |
霍夫曼-拉罗奇有限公司 |
改进的等位基因特异性扩增
|
CN101724144A
(zh)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
新型的多臂聚乙二醇及其制备方法和应用
|
CN102203296B
(zh)
*
|
2008-11-05 |
2014-12-03 |
健泰科生物技术公司 |
年龄相关的黄斑变性中的遗传多态性
|
WO2010075519A2
(en)
|
2008-12-23 |
2010-07-01 |
Massachusetts Eye & Ear Infirmary |
Allelic variants associated with advanced age-related macular degeneration
|
US20100174272A1
(en)
|
2009-01-02 |
2010-07-08 |
Weiner Alan L |
In-situ refillable ophthalmic implant
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
PL2391419T3
(pl)
|
2009-01-29 |
2019-12-31 |
Forsight Vision4, Inc. |
Dostarczanie leku do tylnego odcinka
|
WO2010132459A2
(en)
*
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
CN107858381A
(zh)
|
2009-07-02 |
2018-03-30 |
朗泽科技新西兰有限公司 |
醇生产方法
|
CA2781595C
(en)
*
|
2009-07-10 |
2016-07-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
US20120190578A1
(en)
|
2009-08-06 |
2012-07-26 |
Washington University |
Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
EA021356B1
(ru)
|
2009-11-19 |
2015-05-29 |
Мерк Сероно С.А. |
Гуманизированные антитела против il-22ra человека
|
EP2507381A4
(en)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
|
CN103755949B
(zh)
|
2009-12-25 |
2016-04-13 |
天津键凯科技有限公司 |
多臂聚乙二醇衍生物及其与药物的结合物和凝胶
|
AU2011323487B2
(en)
|
2010-11-01 |
2016-08-11 |
Genentech, Inc. |
Predicting progression to advanced age-related macular degeneration using a polygenic score
|
WO2012082912A2
(en)
*
|
2010-12-14 |
2012-06-21 |
Tufts Medical Center, Inc. |
Markers related to age-related macular degeneration and uses therefor
|
JP5942171B2
(ja)
*
|
2011-03-30 |
2016-06-29 |
パナソニックIpマネジメント株式会社 |
車載用充電装置
|
KR102102862B1
(ko)
|
2011-10-14 |
2020-04-22 |
제넨테크, 인크. |
항-HtrA1 항체 및 사용 방법
|
JP6051998B2
(ja)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
EP3042205B1
(en)
|
2013-09-06 |
2019-12-25 |
F. Hoffmann-La Roche AG |
Method for improving antibody stability
|
BR112016025312A2
(pt)
|
2014-05-01 |
2017-10-17 |
Genentech Inc |
variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
|